Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. [PDF]
Fitzgerald L +13 more
europepmc +1 more source
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders. [PDF]
Duminuco A +9 more
europepmc +1 more source
Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus. [PDF]
D'Amato M +17 more
europepmc +1 more source
Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter's syndrome. [PDF]
Meier T +4 more
europepmc +1 more source
First-line treatment for CLL in the era of targeted therapy. [PDF]
Davids MS, Stilgenbauer S, Tam CS.
europepmc +1 more source
Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. [PDF]
Hetta HF +14 more
europepmc +1 more source
Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients. [PDF]
Dingli D +10 more
europepmc +1 more source
Leukemic penile ulcer as the presenting symptom of chronic lymphatic leukemia. [PDF]
Sandhu HS, Chandra S, Joshi S.
europepmc +1 more source
Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]
Al-Shaker AN +3 more
europepmc +1 more source

